Jacqueline Studer - IDEXX Laboratories President
| IDXX Stock | USD 468.04 24.72 5.02% |
President
Ms. Jacqueline L. Studer is no longer Corporationrationrate Vice President, General Counsel and Corporationrationrate Secretary of IDEXX Laboratories, Inc., effective March 1, 2019. Ms. Studer was Corporationrationrate Vice President, General Counsel and Corporationrationrate Secretary since September 2014. She leads the Companys legal, compliance, regulatory affairs and quality assurance groups. Before joining the Company, Ms. Studer was Vice President, General Counsel and Secretary of Blue Health Intelligence, a healthcare data and analytics company. Prior to that, from June 2011 to October 2012, Ms. Studer served as Executive Vice President and General Counsel of Allscripts Healthcare Solutions. From December 2002 to June 2011, Ms. Studer held various leadership positions at GE Healthcare, a medical technology company, including General Counsel of the GE Healthcare IT Performance Solutions division. Ms. Studer has also held leadership roles in entrepreneurial organizations and with The Dow Chemical Company earlier in her career since 2014.
| Age | 58 |
| Tenure | 10 years |
| Address | One IDEXX Drive, Westbrook, ME, United States, 04092 |
| Phone | 207 556 0300 |
| Web | https://www.idexx.com |
IDEXX Laboratories Management Efficiency
The company has return on total asset (ROA) of 0.2283 % which means that it generated a profit of $0.2283 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.8074 %, meaning that it created $0.8074 on every $100 dollars invested by stockholders. IDEXX Laboratories' management efficiency ratios could be used to measure how well IDEXX Laboratories manages its routine affairs as well as how well it operates its assets and liabilities. At this time, IDEXX Laboratories' Return On Tangible Assets are fairly stable compared to the past year. Return On Assets is likely to rise to 0.27 in 2024, whereas Return On Capital Employed is likely to drop 0.26 in 2024. At this time, IDEXX Laboratories' Return On Assets are fairly stable compared to the past year.Similar Executives
| Showing other executives | PRESIDENT Age | ||
| Robert McMahon | Agilent Technologies | 55 | |
| Sam Samad | Illumina | 48 | |
| William Daniel | Danaher | 53 | |
| James Ditkoff | Danaher | 67 | |
| Nicholas Naclerio | Illumina | 53 | |
| Peter Hornstra | Thermo Fisher Scientific | 59 | |
| Joakim Weidemanis | Danaher | 55 | |
| Ian King | Waters | 63 | |
| Sanjay Chikarmane | Illumina | N/A | |
| Garret Hampton | Illumina | 52 | |
| Rodney Gonsalves | Agilent Technologies | 58 | |
| Samraat Raha | Agilent Technologies | 51 | |
| Gregory Herrema | Thermo Fisher Scientific | 52 | |
| Francis Kim | Waters | 51 | |
| Angela Lalor | Danaher | 59 | |
| Andrew Thomson | Thermo Fisher Scientific | 49 | |
| Robert Lutz | Danaher | 62 | |
| Paula Dowdy | Illumina | N/A | |
| Mark Oene | Illumina | 45 | |
| Michael Tang | Agilent Technologies | 50 | |
| Patrick Kaltenbach | Agilent Technologies | 53 | |
Management Performance
| Return On Equity | 0.81 | ||||
| Return On Asset | 0.23 |
IDEXX Laboratories Leadership Team
Elected by the shareholders, the IDEXX Laboratories' board of directors comprises two types of representatives: IDEXX Laboratories inside directors who are chosen from within the company, and outside directors, selected externally and held independent of IDEXX. The board's role is to monitor IDEXX Laboratories' management team and ensure that shareholders' interests are well served. IDEXX Laboratories' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, IDEXX Laboratories' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Kathy Turner, Corporate Vice President | ||
| Sophie Vandebroek, Director | ||
| Jonathan Ayers, Chairman, CEO and Pres | ||
| William End, Lead Independent Director | ||
| Jacqueline Studer, Corporate Vice President General Counsel, Secretary | ||
| Johnny Powers, Executive VP | ||
| Rebecca Henderson, Independent Director | ||
| Michael Lane, Corporate Vice President General Manager | ||
| Anne Szostak, Independent Director | ||
| George Fennell, Senior Officer | ||
| Sharon Underberg, Corporate Vice President General Counsel, and Corporate Secretary | ||
| Ken Grady, Senior Officer | ||
| Jay Mazelsky, Executive VP | ||
| Stuart Essig, Independent Director | ||
| M Szostak, Independent Director | ||
| Bruce Claflin, Independent Director | ||
| Sam Samad, Independent Director | ||
| Barry Johnson, Independent Director | ||
| Giovani Twigge, Chief Human Resource Officer, Corporate Vice President | ||
| Nimrata PE, Sector Strategy | ||
| Martin Smith, Executive CTO | ||
| Jeffery Chadbourne, Director Reporting | ||
| Daniel Junius, Independent Director | ||
| Lawrence Kingsley, Independent Director | ||
| Kerry Bennett, Senior Labs | ||
| Thomas Craig, Independent Director | ||
| Michael Johnson, Executive Officer | ||
| Jonathan Mazelsky, CEO President | ||
| James Polewaczyk, Executive Officer | ||
| John Hart, Senior Operations | ||
| Michael Williams, Executive VP | ||
| Pat Venters, Chief Marketing Officer, Vice President | ||
| Brian McKeon, CFO, Principal Accounting Officer, Executive VP and Treasurer |
IDEXX Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is IDEXX Laboratories a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.81 | ||||
| Return On Asset | 0.23 | ||||
| Profit Margin | 0.23 % | ||||
| Operating Margin | 0.27 % | ||||
| Current Valuation | 41.56 B | ||||
| Shares Outstanding | 83.05 M | ||||
| Shares Owned By Insiders | 0.92 % | ||||
| Shares Owned By Institutions | 92.01 % | ||||
| Number Of Shares Shorted | 1.71 M | ||||
| Price To Earning | 61.31 X |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in IDEXX Laboratories. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in interest. For more information on how to buy IDEXX Stock please use our How to Invest in IDEXX Laboratories guide.You can also try the Headlines Timeline module to stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity.
Complementary Tools for IDEXX Stock analysis
When running IDEXX Laboratories' price analysis, check to measure IDEXX Laboratories' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy IDEXX Laboratories is operating at the current time. Most of IDEXX Laboratories' value examination focuses on studying past and present price action to predict the probability of IDEXX Laboratories' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move IDEXX Laboratories' price. Additionally, you may evaluate how the addition of IDEXX Laboratories to your portfolios can decrease your overall portfolio volatility.
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Stocks Directory Find actively traded stocks across global markets | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities |
Is IDEXX Laboratories' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of IDEXX Laboratories. If investors know IDEXX will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about IDEXX Laboratories listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.121 | Earnings Share 10.05 | Revenue Per Share 44.073 | Quarterly Revenue Growth 0.088 | Return On Assets 0.2283 |
The market value of IDEXX Laboratories is measured differently than its book value, which is the value of IDEXX that is recorded on the company's balance sheet. Investors also form their own opinion of IDEXX Laboratories' value that differs from its market value or its book value, called intrinsic value, which is IDEXX Laboratories' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because IDEXX Laboratories' market value can be influenced by many factors that don't directly affect IDEXX Laboratories' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between IDEXX Laboratories' value and its price as these two are different measures arrived at by different means. Investors typically determine if IDEXX Laboratories is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, IDEXX Laboratories' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.